Abstract
Maternal Phenylketonuria Syndrome (MPKU) can occur in infants born to mothers with PKU with poor metabolic control during pregnancy. Elevated phenylalanine (phe) acts as a teratogen to the developing fetus with consequences including intellectual disability, microcephaly, facial dysmorphism, growth retardation, and congenital heart disease. MPKU can be prevented if metabolic control is achieved by 8–10 weeks gestation. If control is not achieved, there is a significant risk for MPKU. Therefore, in women with poor metabolic control at time of pregnancy, establishing metabolic control quickly is important.
Clinically, establishing metabolic control in women with PKU can present challenges. Social issues, psychological issues, and insufficient education about PKU play an important role in a patient’s inability to reinstitute this challenging diet. Maintaining phe levels within a range to allow for infant growth, while preventing toxicity, is challenging, particularly for those women who no longer follow the PKU diet. Gastrostomy tube placement is an option to deliver medical formula to women who are unable to restart diet due to severe nausea or palatability issues.
Here we discuss two pregnancies in which a gastrostomy tube was placed to achieve metabolic control after other measures failed to reduce phe concentrations into the recommended range. For these two pregnancies, placement of the gastrostomy tube led to improvement in phe levels with normal infant outcomes including normal growth, head circumference, and heart structure.
Competing interests: None declared
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Abbreviations
- CHD:
-
Congenital heart disease
- Gm:
-
Grams
- Kcals:
-
Kilocalories
- MPKU:
-
Maternal phenylketonuria syndrome
- phe:
-
Phenylalanine
- PKU:
-
Phenylketonuria
- U.S:
-
United States
- Kg:
-
Kilogram
- cm:
-
centimeter
References
Allaert SE, Carlier SP, Weyne LP, Vertommen DJ, Dutre PE, Desmet MB (2007) First trimester anesthesia exposure and fetal outcome. A review. Acta Anaesthesiol Belg 58(2):119–123
Brown AS, Fernhoff PM, Waisbren SE et al (2002) Barriers to successful dietary control among pregnant women with phenylketonuria. Genet Med 4(2):84–89
Cheek TG, Baird E (2009) Anesthesia for nonobstetric surgery: maternal and fetal considerations. Clin Obstet Gynecol 52(4):535–545
Godil A, Chen YK (1998) Percutaneous endoscopic gastrostomy for nutrition support in pregnancy associated with hyperemesis gravidarum and anorexia nervosa. J Parenter Enteral Nutr 22(4):238–241
Irving PM, Howell RJ, Shidrawi RG (2004) Percutaneous endoscopic gastrostomy with a jejunal port for severe hyperemesis gravidarum. Eur J Gastroen Hepat 16(9):937–939
Koch R (2008) Maternal phenylketonuria and tetrahydrobiopterin. Pediatrics 122:1367
Koch R, Levy HL, Matalon R, Rouse B, Hanely W, Azen C (1993) The North American collaborative study of maternal phenylketonuria. Am J Dis Child 147:1224–1230
Koch R, Hanley W, Levy HL et al (2000) Maternal pheylketonuria: an international study. Mol Genet Metab 71:233–239
Koch R, Moseley K, Guttler F (2005) Tetrahydrobiopterin and maternal PKU. Mol Genet Metab 86:S139–S141
Koh ML, Lipkin EW (1993) Nutrition support of a pregnant comatose patient via percutaneous endoscopic gastrostomy. J Parenter Enteral Nutr 17(4):384–387
Kuczkowski KM (2004) Nonobstetric surgery during pregnancy: what are the risks of anesthesia? Obstet Gynecol Surv 59(1):52–56
Lee PJ, Lilburn M, Baudin J (2003) Maternal phenylketonuria: experiences from the United Kingdom. Pediatrics 112(6):1553–1556
Lee P, Treacy EP, Crombez E et al (2008) Safety and efficacy of 22 weeks of treatment with sapropterin dihydrochloride in patients with phenylketonuria. Am J Med Genet 146A:2851–2859
Lenke RR, Levy HL (1980) Maternal phenylketonuria and hyperphenylalaninemia: an international survey of outcome of untreated and treated pregnancies. N Engl J Med 202(21):1202–1208
Levy HL (2003) Historical background for the maternal PKU syndrome. Pediatrics 112:1516–1518
Levy HL, Ghavami M (1996) Maternal phenylketonuria: a metabolic teratogen. Teratology 53:176–184
Levy HL, Guldberg P, Guttler F et al (2001) Congenital heart disease in maternal phenylketonuria: report from the maternal PKU collaborative study. Pediatr Res 49(5):636–642
MacDonald A, Rylance G, Hall SK, Asplin D, Booth IW (1996) Factors affecting the variation in plasma phenylalanine in patients with phenylketonuria on diet. Arch Dis Child 74:412–417
Matalon KM, Acosta PB, Azen C (2003) Role of nutrition in pregnancy with phenylketonuria and birth defects. Pediatrics 112(6):1534–1536
Medical Advisory Panel of the National Society for Phenylketonuria (2004) Management of PKU. The National Society for Phenylketonuria (United Kingdom) Ltd.
National Institutes of Health Consensus Development Panel (2001) National Institutes of Health Consensus Development conference statement; phenylketonuria: screening and management. Pediatrics 108(4):972–979
Pendlebury J, Phillips F, Ferguson A, Ghost S (1997) Successful pregnancy in a patient with chronic intestinal pseudo-obstruction while on ambulatory percutaneous endoscopic gastrostomy feeding. Eur J Gastroenterol Hepat 9(7):711–713
Pridjian G, Cunningham A, Tafti S, Andersson H (2008) PKU treatment with tetrahydrobiopterin (sapropterin) during pregnancy. The American Society of Human Genetics 58th annual meeting, Philadelphia, November 11–15, 2008
Rashad MS, Ozand PT, Bucknall MP, Little D (1995) Diagnosis of inborn errors of metabolism from blood spots by acylcarnitine and amino acid profiling using automated electospray tandem mass spectrometry. Pediatr Res 38:324–331
Rouse B, Matalon R, Koch R et al (2000) Maternal phenylketonuria syndrome: congenital heart defects, microcephaly and developmental outcomes. Pediatrics 136(1):57–61
Saha S, Loranger D, Pricolo V, Degli-Esposti S (2009) Feeding jejunostomy for the treatment of severe hyperemesis gravidarum: a case series. J Parenter Enteral Nutr 33(5):529–534
Serrano P, Velloso A, García-Luna PP et al (1998) Enteral nutrition by percutaneous endoscopic gastrojejunostomy in severe hyperemesis gravidarum: a report of two cases. Clin Nutr 17(3):135–139
Shaheen NJ, Crosby MA, Grimm IS, Isaacs K (1997) The use of percutaneous endoscopic gastrostomy in pregnancy. Gastrointest Endosco 46(6):564–565
Slocum RH, Cummings JG (1991) Amino acid analysis of physiological samples. In: Hommes FA (ed) Techniques in diagnostic human biochemical genetics: a laboratory manual. Wiley-Liss, New York, pp 87–126
Trefz FK, Blau N (2003) Potential role of tetrahydrobiopterin in the treatment of maternal phenylketonuria. Pediatrics 112(6):1566–1569
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Additional information
Communicated by: John H Walter
Appendices
Synopsis Statement
Gastrostomy tube placement in pregnant women with phenylketonuria is another option to control phenylalanine levels and prevent maternal PKU syndrome.
Jessica Scott Schwoerer
Conflict of Interest Questions
-
1.
Have you in the past 5 years accepted the following from an organization that may in any way gain or lose financially from the result of your study or the conclusion of your review, editorial, or letter:
-
a.
Reimbursement for attending a symposium? – No
-
b.
A fee for specking or for organizing education? – No
-
c.
Funds for research or for a member of staff – No
-
d.
A fee for consulting? – No
-
a.
-
2.
Have you in the past five years been employed by an organization that may in any way gain or lose financially from the result of your study or the conclusion of your review, editorial, or letter? No. Do you hold any stocks or shares in such an organization? No
-
3.
Have you acted as an expert witness on the subject of your study, review, editorial, or letter? No
-
4.
Do you have any other competing financial interests? No
Gregory Rice
Conflict of Interest Questions
-
1.
Have you in the past 5 years accepted the following from an organization that may in any way gain or lose financially from the result of your study or the conclusion of your review, editorial, or letter:
-
a.
Reimbursement for attending a symposium? – Yes, BioMarin Pharmaceuticals, Kuvan Advisory Meeting 2009. I do not believe that this publication will have any financial effect on the above but I am disclosing the relationship for completeness.
-
b.
A fee for specking or for organizing education? – Yes, BioMarin Pharmaceuticals, Kuvan Advisory Meeting 2010. I do not believe that this publication will have any financial effect on the above but I am disclosing the relationship for completeness.
-
c.
Funds for research or for a member of staff – Yes, we are involved in clinical trials sponsored by BioMarin Pharmaceuticals. I do not believe that this publication will have any financial effect on the above but I am disclosing the relationship for completeness.
-
d.
A fee for consulting? – No
-
a.
-
2.
Have you in the past 5 years been employed by an organization that may in any way gain or lose financially from the result of your study or the conclusion of your review, editorial, or letter? No. Do you hold any stocks or shares in such an organization? No
-
3.
Have you acted as an expert witness on the subject of your study, review, editorial, or letter? No
-
4.
Do you have any other competing financial interests? No
Rights and permissions
Copyright information
© 2012 SSIEM and Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Schwoerer, J.A.S. et al. (2012). Use of Gastrostomy Tube to Prevent Maternal PKU Syndrome. In: JIMD Reports - Case and Research Reports, 2012/3. JIMD Reports, vol 6. Springer, Berlin, Heidelberg. https://doi.org/10.1007/8904_2011_95
Download citation
DOI: https://doi.org/10.1007/8904_2011_95
Received:
Revised:
Accepted:
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-28128-0
Online ISBN: 978-3-642-28129-7
eBook Packages: MedicineMedicine (R0)